ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 100 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $4,989,000 | -9.6% | 398,499 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $5,519,000 | +58.4% | 398,499 | +13.0% | 0.00% | 0.0% |
| Q2 2016 | $3,485,000 | -37.7% | 352,706 | +6.6% | 0.00% | 0.0% |
| Q1 2016 | $5,596,000 | -23.0% | 330,950 | +1.4% | 0.00% | 0.0% |
| Q4 2015 | $7,267,000 | -3.8% | 326,479 | +2.0% | 0.00% | 0.0% |
| Q3 2015 | $7,553,000 | -69.7% | 320,172 | +5.2% | 0.00% | -75.0% |
| Q2 2015 | $24,889,000 | +31.0% | 304,420 | +48.4% | 0.00% | +33.3% |
| Q1 2015 | $19,000,000 | +441.2% | 205,188 | +136.3% | 0.00% | +200.0% |
| Q4 2014 | $3,511,000 | +104.0% | 86,830 | +23.4% | 0.00% | – |
| Q3 2014 | $1,721,000 | +47.7% | 70,349 | -4.3% | 0.00% | – |
| Q2 2014 | $1,165,000 | +3.4% | 73,525 | -1.4% | 0.00% | – |
| Q1 2014 | $1,127,000 | -12.0% | 74,565 | -20.0% | 0.00% | – |
| Q4 2013 | $1,280,000 | -15.0% | 93,193 | +16.8% | 0.00% | – |
| Q3 2013 | $1,505,000 | – | 79,773 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |